FDA Approves Futibatinib for Certain Biliary Tract Cancers FDA Approves Futibatinib for Certain Biliary Tract Cancers

The indication is for use in adult patients with previously treated intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news